APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G
- PMID: 17121840
- DOI: 10.1074/jbc.M607298200
APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G
Abstract
APOBEC3F (apolipoprotein B mRNA-editing enzyme catalytic polypeptide 1-like protein 3F) is a cytidine deaminase that, like APOBEC3G, is able to restrict the replication of HIV-1/delta vif. Initial studies revealed high numbers of mutations in the cDNA of viruses produced in the presence of these proteins, suggesting that cytidine deamination underpinned the inhibition of infection. However, we have recently shown that catalytically inactive APOBEC3G proteins, derived through mutation of the C-terminal cytidine deaminase motif, still exert a substantial antiviral effect. Here, we have generated a panel of APOBEC3F mutant proteins and show that the C-terminal cytidine deaminase motif is essential for catalytic activity and that catalytic activity is not necessary for the antiviral effect of APOBEC3F. Furthermore, we demonstrate that the antiviral activities of wild-type and catalytically inactive APOBEC3F and APOBEC3G proteins correspond well with reductions in the accumulation of viral reverse transcription products. Additional comparisons between APOBEC3F and APOBEC3G suggest that the loss of deaminase activity is more detrimental to APOBEC3G function than to APOBEC3F function, as reflected by perturbations to the suppression of reverse transcript accumulation as well as antiviral activity. Taken together, these data suggest that both APOBEC3F and APOBEC3G are able to function as antiviral factors in the absence of cytidine deamination, that this editing-independent activity is an important aspect of APOBEC protein-mediated antiviral phenotypes, but that APOBEC3F may be a better model in which to study it.
Similar articles
-
Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.J Virol. 2006 Sep;80(17):8450-8. doi: 10.1128/JVI.00839-06. J Virol. 2006. PMID: 16912295 Free PMC article.
-
Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.J Virol. 2007 Jul;81(13):7238-48. doi: 10.1128/JVI.02584-06. Epub 2007 Apr 11. J Virol. 2007. PMID: 17428847 Free PMC article.
-
Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle.J Biol Chem. 2007 Jan 19;282(3):1585-94. doi: 10.1074/jbc.M610150200. Epub 2006 Dec 1. J Biol Chem. 2007. PMID: 17142455 Free PMC article.
-
APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.Med Sci Monit. 2006 May;12(5):RA92-8. Med Sci Monit. 2006. PMID: 16641889 Review.
-
Antiviral roles of APOBEC proteins against HIV-1 and suppression by Vif.Arch Virol. 2009;154(10):1579-88. doi: 10.1007/s00705-009-0481-y. Epub 2009 Aug 12. Arch Virol. 2009. PMID: 19669862 Review.
Cited by
-
Identification of the feline foamy virus Bet domain essential for APOBEC3 counteraction.Retrovirology. 2013 Jul 24;10:76. doi: 10.1186/1742-4690-10-76. Retrovirology. 2013. PMID: 23880220 Free PMC article.
-
The von Hippel-Lindau Cullin-RING E3 ubiquitin ligase regulates APOBEC3 cytidine deaminases.Transl Res. 2021 Nov;237:1-15. doi: 10.1016/j.trsl.2021.05.002. Epub 2021 May 15. Transl Res. 2021. PMID: 34004371 Free PMC article.
-
Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo.Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3035-40. doi: 10.1073/pnas.1111573109. Epub 2012 Feb 6. Proc Natl Acad Sci U S A. 2012. PMID: 22315404 Free PMC article.
-
The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains.Virology. 2007 Aug 1;364(2):486-93. doi: 10.1016/j.virol.2007.03.019. Epub 2007 Apr 16. Virology. 2007. PMID: 17434555 Free PMC article.
-
APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.J Virol. 2010 Jul;84(14):7396-404. doi: 10.1128/JVI.00056-10. Epub 2010 May 12. J Virol. 2010. PMID: 20463080 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases